CEL-SCI (CVM)
Develops a pre-surgical cytokine treatment for selected head-and-neck cancer patients.
Something off on this page? Send us feedback.
Develops Multikine, a pre-surgical cytokine treatment for selected head-and-neck cancer patients, and retains a preclinical LEAPS platform. With no approved products or product revenue, operations are concentrated on a confirmatory study, specialized biologic manufacturing and external financing.
Develops Multikine, a locally administered mixture of naturally derived human cytokines intended as a pre-surgical treatment for selected patients with newly diagnosed head-and-neck squamous cell carcinoma. It is designed to add to, rather than replace, surgery and postoperative radiation or chemoradiation. LEAPS, an antigen-presentation platform, remains preclinical and is not the present research-and-development focus.
Operates as a research-and-development business with no approved products or product revenue. Controls Multikine development and biologic manufacturing at a dedicated Maryland facility, while using clinical and regulatory contractors and maintaining prospective territory agreements that depend on future approvals.
Depends on a confirmatory late-stage study for patients with low or absent PD-L1 expression and no clinical lymph-node involvement at entry, after the prior full-population study missed its overall-survival endpoint. Commercial deployment would also require regulatory approval, an FDA-authorized companion diagnostic, manufacturing validation, and financing.
Company facts
No analyst consensus on record.
EPSReportedEstimate
RevenueReportedEstimate
Balance sheet, Jun 30, 2026Cash & short-term investments $6.5M · Total debt $7.9M · Total assets $21.4M · Shareholders' equity $11.0M
- Revenue
- $0
- Operating income
- −$5.6M
- Net income
- −$5.7M
No dividends on record.
| Institutions | 29.04% | 2.00M shares | |
|---|---|---|---|
| 40 holders · as of Jun 30, 2026 | |||
| Insiders | 4.60% | 316.1K shares | |
| 1 holder · as of Aug 26, 2026 | |||
| Strategic holders | 8.08% | 555.0K shares | |
| 1 holder · as of Aug 29, 2025 | |||
| Other | 58.28% | 4.00M shares | |
| remainder | |||
6.87M company shares as of Aug 29, 2026 · institutions as of Jun 30, 2026 · holders as of their latest filing
Top shareholders13F · 13D/G · Form 4
| Holder | Stake | Shares | Date |
|---|---|---|---|
Renaissance Technologies LLCInstitution | 8.33% | 572,460 | as of Jun 30, 2026 |
Lincoln Alternative Strategies LLCStrategic | 8.08% | 555,000 | filed Aug 29, 2025 |
Vanguard Capital Management LLCInstitution | 7.90% | 543,079 | as of Jun 30, 2026 |
Geert R. KerstenInsiderdirector, officer: Chief Executive Officer | 4.60% | 316,142 | filed Aug 26, 2026 |
Citadel Advisors LLCInstitution | 2.89% | 198,500 | as of Jun 30, 2026 |
Insider tradesForm 4
| Date | Insider | Role | Shares | Avg price |
|---|---|---|---|---|
| Aug 25, 2026 | Geert R. Kersten | director, officer: Chief Executive Officer | +100,000 | $1.38 |
- Merck
Approved perioperative PD-1 regimen in resectable HNSCC.
- Eli Lilly
Established locoregional HNSCC regimen with radiation.
- Bristol-Myers Squibb
Approved PD-1 therapy in recurrent or metastatic HNSCC.
- PDS Biotechnology
Late-stage HNSCC immunotherapy program targeting HPV16 disease.
Compare
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| CEL-SCI | $1.71 | +0.59% | $11.7M | — | — | — | — |
| Merck | $147.66 | −2.16% | $372.73B | 120.7 | 17.1 | 5.6 | +5.1% |
| Eli Lilly | $1,148.27 | −1.87% | $1.10T | 39.3 | 28.1 | 13.8 | +47.7% |
| Bristol-Myers Squibb | $61.53 | −1.16% | $127.16B | 13.7 | 9.6 | 2.6 | +5.7% |
| PDS Biotechnology | $0.8432 | −7.34% | $50.9M | — | — | — | — |
| Median | 39.3 | 17.1 | 5.6 | +5.7% |